Chemed (CHE) EBITDA (2009 - 2026)

Chemed has reported EBITDA for 18 years, with the latest figure at $89.2 million in Q2 2026.

• EBITDA for Q2 2026 came in at $89.2 million, up 31.02% year-over-year; the trailing twelve-month figure through Jun 2026 was $349.2 million (down 5.34% YoY), and the FY2025 annual result was $338.2 million, down 7.71% from the prior year.
• EBITDA advanced to $89.2 million in Q2 2026, from $84.6 million in the prior quarter.
• Over five years, EBITDA peaked at $113.9 million in Q4 2024 and troughed at $68.1 million in Q2 2025.
• A 5-year average of $86.8 million and a median of $87.5 million in 2023 frame the typical range for EBITDA.
• The largest YoY upside for EBITDA was 36.97% in 2023 against a maximum downside of 24.4% in 2023.
• A 5-year view of EBITDA shows it stood at $81.3 million in 2022, then soared by 36.97% to $111.4 million in 2023, then rose by 2.23% to $113.9 million in 2024, then slipped by 11.61% to $100.7 million in 2025, then fell by 11.38% to $89.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $89.2 million in Q2 2026, $84.6 million in Q1 2026, and $100.7 million in Q4 2025.